Opus Genetics (IRD) Receivables - Net (2012 - 2026)
Opus Genetics (IRD) posted quarterly Receivables - Net of $1.7 million for Q1 2026, down 43.8% year-over-year from $3.1 million in Q1 2025, and down 13.23% quarter-over-quarter from $2.0 million in Q4 2025.
Opus Genetics (IRD) Receivables - Net (2012 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Receivables - Net for 10 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net fell 43.8% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 43.8% YoY), while the FY2025 annual figure was $2.0 million, down 44.01% from the prior year.
- Receivables - Net fell to $1.7 million in Q1 2026 per IRD's latest filing, from $2.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $10.1 million in Q3 2023 and bottomed at $135000.0 in Q2 2023.
- Historically, Receivables - Net has averaged $2.7 million across 5 years, with a median of $2.0 million in 2024.
- On a YoY basis, Receivables - Net climbed as much as 905.93% in 2024 and fell as far as 81.67% in 2024.
- Opus Genetics' Receivables - Net stood at $1.3 million in 2022, then fell by 28.66% to $926000.0 in 2023, then jumped by 284.77% to $3.6 million in 2024, then sank by 44.01% to $2.0 million in 2025, then decreased by 13.23% to $1.7 million in 2026.
- Business Quant data shows IRD's Receivables - Net at $1.7 million in Q1 2026, $2.0 million in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Mn |
| Jun 30, 2026 | 1.04 Mn |
| Mar 31, 2026 | 1.73 Mn |
| Mar 31, 2026 | 1.73 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.92 Mn |
| Mar 31, 2024 | 1.92 Mn |